Individualization of Post-mastectomy Radiotherapy and Regional Nodal Irradiation Based on Treatment Response After Neoadjuvant Chemotherapy for Breast Cancer : A systematic Review

Overview

Journal Strahlenther Onkol

Specialties Oncology
Radiology

Date 2018 Feb 1

PMID 29383405

Citations 18

Authors

David Krug

Rene Baumann

Wilfried Budach

Jurgen Dunst

Petra Feyer

Rainer Fietkau

Wulf Haase

Wolfgang Harms

Thomas Hehr

Marc D Piroth

Felix Sedlmayer

Rainer Souchon

Frederik Wenz

Rolf Sauer

Affiliations

Soon will be listed here.

Abstract

Purpose: To review the evidence regarding post-mastectomy radiotherapy (PMRT) and regional nodal irradiation (RNI) after neoadjuvant chemotherapy (NACT) for breast cancer, with a special focus on individualization of adjuvant radiotherapy based on treatment response.

Methods: A systematic literature search using the PubMed/Medline database was performed. We included prospective and retrospective reports with a minimum of 10 patients that had been published since 1 January 2000, and provided clinical outcome data analyzed by treatment response and radiotherapy.

Results: Out of 763 articles identified via PubMed/Medline and hand search, 68 full text-articles were assessed for eligibility after screening of title and abstract. 13 studies were included in the systematic review, 9 for PMRT and 5 for RNI. All included studies were retrospective reports.

Conclusions: There is a considerable lack of evidence regarding the role of adjuvant radiotherapy and its individualization based on treatment response after NACT. Results of prospective randomized trials such as NSABP B‑51/RTOG 1304 and Alliance A11202 are eagerly awaited.

Citing Articles

Axillary lymph node management strategies in cN + breast cancer patients after neoadjuvant chemotherapy.

Gao M, Chen X, Xu L Clin Transl Oncol. 2024; .

PMID: 39688773 DOI: 10.1007/s12094-024-03817-6.

Somi M, Dolatkhah R, Asvadi Kermani I, Sepahi S, Youzbashi N, Nezamdoust M Asian Pac J Cancer Prev. 2023; 24(6):1905-1916.

PMID: 37378918 PMC: 10505895. DOI: 10.31557/APJCP.2023.24.6.1905.

Clinical feasibility and oncological safety of non-radioactive targeted axillary dissection after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: a prospective diagnostic and prognostic study.

Wu S, Li J, Wang Y, Jin K, Yang B, Li J Int J Surg. 2023; 109(7):1863-1870.

PMID: 37132193 PMC: 10389616. DOI: 10.1097/JS9.0000000000000331.

Axillary response and outcome in breast cancer patients after neoadjuvant treatment: The role of radiotherapy in reducing recurrence in ypN0 patients with initially cN+ stage.

Ren X, Yu Y, Liu L, Xia W, Ni R, Wei S Front Oncol. 2023; 13:1093155.

PMID: 37077821 PMC: 10106717. DOI: 10.3389/fonc.2023.1093155.

Post-Neoadjuvant Treatment Strategies in Breast Cancer.

Matuschek C, Jazmati D, Bolke E, Tamaskovics B, Corradini S, Budach W Cancers (Basel). 2022; 14(5).

PMID: 35267554 PMC: 8909560. DOI: 10.3390/cancers14051246.

References

Bae S, Park W, Huh S, Choi D, Nam S, Im Y . Radiation treatment in pathologic n0-n1 patients treated with neoadjuvant chemotherapy followed by surgery for locally advanced breast cancer. J Breast Cancer. 2012; 15(3):329-36. PMC: 3468787. DOI: 10.4048/jbc.2012.15.3.329. View

Mauri D, Pavlidis N, Ioannidis J . Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005; 97(3):188-94. DOI: 10.1093/jnci/dji021. View

Rea D, Francis A, Hanby A, Speirs V, Rakha E, Shaaban A . Inflammatory breast cancer: time to standardise diagnosis assessment and management, and for the joining of forces to facilitate effective research. Br J Cancer. 2015; 112(9):1613-5. PMC: 4453671. DOI: 10.1038/bjc.2015.115. View

White J, Mamounas E . Locoregional radiotherapy in patients with breast cancer responding to neoadjuvant chemotherapy: a paradigm for treatment individualization. J Clin Oncol. 2014; 32(6):494-5. PMC: 5612477. DOI: 10.1200/JCO.2013.53.4974. View

McGale P, Cutter D, Darby S, Henson K, Jagsi R, Taylor C . Can Observational Data Replace Randomized Trials?. J Clin Oncol. 2016; 34(27):3355-7. DOI: 10.1200/JCO.2016.68.8879. View

Shim S, Park W, Huh S, Choi D, Shin K, Lee N . The role of postmastectomy radiation therapy after neoadjuvant chemotherapy in clinical stage II-III breast cancer patients with pN0: a multicenter, retrospective study (KROG 12-05). Int J Radiat Oncol Biol Phys. 2013; 88(1):65-72. DOI: 10.1016/j.ijrobp.2013.09.021. View

Mieog J, van der Hage J, van de Velde C . Neoadjuvant chemotherapy for operable breast cancer. Br J Surg. 2007; 94(10):1189-200. DOI: 10.1002/bjs.5894. View

Cassidy R, Liu Y, Kahn S, Jegadeesh N, Liu X, Subhedar P . The role of postmastectomy radiotherapy in women with pathologic T3N0M0 breast cancer. Cancer. 2017; 123(15):2829-2839. DOI: 10.1002/cncr.30675. View

Wenz F, Sperk E, Budach W, Dunst J, Feyer P, Fietkau R . DEGRO practical guidelines for radiotherapy of breast cancer IV: radiotherapy following mastectomy for invasive breast cancer. Strahlenther Onkol. 2014; 190(8):705-14. DOI: 10.1007/s00066-014-0687-0. View

10.

Poortmans P, Collette S, Kirkove C, Van Limbergen E, Budach V, Struikmans H . Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer. N Engl J Med. 2015; 373(4):317-27. DOI: 10.1056/NEJMoa1415369. View

11.

Rusthoven C, Rabinovitch R, Jones B, Koshy M, Amini A, Yeh N . The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysis. Ann Oncol. 2016; 27(5):818-27. DOI: 10.1093/annonc/mdw046. View

12.

Le Scodan R, Selz J, Stevens D, Bollet M, De La Lande B, Daveau C . Radiotherapy for stage II and stage III breast cancer patients with negative lymph nodes after preoperative chemotherapy and mastectomy. Int J Radiat Oncol Biol Phys. 2011; 82(1):e1-7. DOI: 10.1016/j.ijrobp.2010.12.054. View

13.

Gianni L, Pienkowski T, Im Y, Roman L, Tseng L, Liu M . Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2011; 13(1):25-32. DOI: 10.1016/S1470-2045(11)70336-9. View

14.

Johnson M, Handorf E, Martin J, Hayes S . Postmastectomy radiation therapy for T3N0: a SEER analysis. Cancer. 2014; 120(22):3569-74. PMC: 4413466. DOI: 10.1002/cncr.28865. View

15.

Marks L, Prosnitz L . Reducing local therapy in patients responding to preoperative systemic therapy: are we outsmarting ourselves?. J Clin Oncol. 2014; 32(6):491-3. DOI: 10.1200/JCO.2013.51.3523. View

16.

. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2017; 19(1):27-39. PMC: 5757427. DOI: 10.1016/S1470-2045(17)30777-5. View

17.

Dawood S, Merajver S, Viens P, Vermeulen P, Swain S, Buchholz T . International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol. 2010; 22(3):515-523. PMC: 3105293. DOI: 10.1093/annonc/mdq345. View

18.

Fowble B, Einck J, Kim D, McCloskey S, Mayadev J, Yashar C . Role of postmastectomy radiation after neoadjuvant chemotherapy in stage II-III breast cancer. Int J Radiat Oncol Biol Phys. 2012; 83(2):494-503. DOI: 10.1016/j.ijrobp.2012.01.068. View

19.

Budach W, Bolke E, Kammers K, Gerber P, Nestle-Kramling C, Matuschek C . Adjuvant radiation therapy of regional lymph nodes in breast cancer - a meta-analysis of randomized trials- an update. Radiat Oncol. 2015; 10:258. PMC: 4687086. DOI: 10.1186/s13014-015-0568-4. View

20.

Nagar H, Mittendorf E, Strom E, Perkins G, Oh J, Tereffe W . Local-regional recurrence with and without radiation therapy after neoadjuvant chemotherapy and mastectomy for clinically staged T3N0 breast cancer. Int J Radiat Oncol Biol Phys. 2011; 81(3):782-7. DOI: 10.1016/j.ijrobp.2010.06.027. View